Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

Royalty revenue contribution expected to begin as early as 2030

Initial partner targets include derisked MoAs that are approved blockbusters today

Highly scalable licensing model and long duration IP into 2040s; potential for individual product IP extension through proprietary reformulation

Read more at prnewswire.com